The Impacts of Rescheduling Cannabis
Rescheduling cannabis to Schedule III aims to balance medical use with controlling abuse potential. Ultimately, moving cannabis to Schedule III has the potential to drastically transform the operational, financial, and legal framework for all players in the cannabis sector, paving the way for extensive research, broader access, and greater acceptance.
Compliance
Registration
Entities need to register with state medical marijuana programs and the DEA for legal handling of these substances.
Inventory Management
Keep precise records of inventory receipts, distribution, and disposal.
Comprehensive Manufacturing Plan
Must demonstrate cGMP manufacturing.
Security Measures
Facilities require strong security, including alarms, surveillance, and secure storage, to deter theft and unauthorized access.
Reporting and Recordkeeping:
Keep precise records of inventory receipts, distribution, and disposal.
Federal and State Regulations:
Adherence to both federal and, in some cases, more stringent state regulations is required.
Training and Education:
Staff handling these substances should be trained in relevant laws and best practices.
Audits and Inspections:
Facilities may undergo audits and inspections by state medical marijuana authorities and the DEA to ensure compliance.
Reporting Suspicious Activity:
Any suspicious activities related to the diversion or misuse of these substances must be reported to the authorities.
Registration
Entities need to register with state medical marijuana programs and the DEA for legal handling of these substances.
Inventory Management
Keep precise records of inventory receipts, distribution, and disposal.
Comprehensive Manufacturing Plan
Must demonstrate cGMP manufacturing.
Security Measures
Facilities require strong security, including alarms, surveillance, and secure storage, to deter theft and unauthorized access.
Reporting and Recordkeeping
Keep precise records of inventory receipts, distribution, and disposal.
Federal and State Regulations:
Adherence to both federal and, in some cases, more stringent state regulations is required.
Training and Education
Staff handling these substances should be trained in relevant laws and best practices.
Audits and Inspections
Facilities may undergo audits and inspections by state medical marijuana authorities and the DEA to ensure compliance.
Reporting Suspicious Activity
Any suspicious activities related to the diversion or misuse of these substances must be reported to the authorities.
Registration
Entities need to register with state medical marijuana programs and the DEA for legal handling of these substances.
Inventory Management
Keep precise records of inventory receipts, distribution, and disposal.
Comprehensive Manufacturing Plan
Must demonstrate cGMP manufacturing.
Security Measures
Facilities require strong security, including alarms, surveillance, and secure storage, to deter theft and unauthorized access.
Reporting and Recordkeeping
Keep precise records of inventory receipts, distribution, and disposal.
Federal and State Regulations:
Adherence to both federal and, in some cases, more stringent state regulations is required.
Training and Education
Staff handling these substances should be trained in relevant laws and best practices.
Audits and Inspections
Facilities may undergo audits and inspections by state medical marijuana authorities and the DEA to ensure compliance.
Reporting Suspicious Activity
Any suspicious activities related to the diversion or misuse of these substances must be reported to the authorities.
Research & Development
Schedule I restrictions put extreme limits on growth opportunities, research and clinical studies for cannabis. Schedule III would open the door for funding & research.
Growth Opportunities
Regulatory barriers hinder cannabinoid research in the US, preventing therapeutic performance studies. Rescheduling cannabis to Schedule III would ease restrictions, enabling research and aligning state and federal laws, fostering studies on non-psychotropic cannabinoids like CBD.
Clinical Studies
Schedule I status restricts cannabis research. Rescheduling would facilitate study approvals and funding, encouraging the development of new medications. Recent legislative changes, such as HR-8454, support efficacy testing on cannabinoids. Kazmira is pursuing clinical studies to validate the effectiveness of products like Imperial Oil® and Silver Plume®.
Medical Applications Mentioned by HHS
Mentioned by HHS
The Department of Health and Human Services (HHS) regognizes the medical value of cannabis and mentioned specific application opportunities for cannabis in Schedule III.
Inflammatory
Conditions
Nausea and
Vomiting
Pain
Management
Neurological
Disorders
Mental Health
Disorders
Appetite
Stimulation
Inflammatory
Conditions
Nausea and
Vomiting
Neurological
Disorders
Pain
Management
Mental Health
Disorders
Appetite Stimulation
Food and Drug Administration (FDA) Disclaimer
These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure or prevent any disease.
Terms & Conditions | Privacy Policy | Shipping & Return Policy | FDA Disclaimer
